Business
Immune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal™ for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster
Immune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal™ for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nImmune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal™ for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nImmune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal™ for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster\nPR Newswire\nWASHINGTON, Oct. 26, 2016\n\n\n\nWASHINGTON, Oct. 26, 2016 /PRNewswire/ -- Immune Therapeutics, Inc. (OTCQB: IMUN) (the \"Company\"), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer, today announced that the Ministry of Health and Prevention Division of Pharmacy in the Republic of Senegal (the \"Ministry of Health\") accepted for review the Company's New Drug Applications (\"NDAs\") for LodonalTM as a stand alone or adjunct therapy non-toxic in the treatment of HIV/AIDS, cancer and as an immune booster. \n\nThe NDAs for LodonalTM are based on clinical data provided from Phase II trials in the United States, two Phase II trials for HIV in the  Republic of Mali in West Africa, and the drug approval in the Republic of Nigeria as an immune system regulating agent in patients with Human Immuno-Deficiency Virus (HIV).  LodonalTM met the primary and secondary endpoints for both efficacy and safety in its clinical trial in Nigeria. \n\nWhile this data supports the acceptance of the NDAs by the Ministry of Health, this acceptance does not guarantee that LodonalTM will be approved by the Ministry of Health for the treatment of adults with HIV/AIDS, immuno-deficiency and/or cancer. \n\n\"LodonalTM demonstrates Immune Therapeutics' commitment to delivering affordable non-toxic innovative therapies for patients with chronic illness\" said Professor Shan, the Company's Chief Science Officer and Head of Global Clinical Development. \"If approved, LodonalTM would be the first affordable non-toxic therapy for the treatment of patients with HIV and cancer. We look forward to ...